Loading clinical trials...
Loading clinical trials...
An Open-Label Study of Regorafenib in Combination With Pembrolizumab in Patients With Advanced or Metastatic Hepatocellular Carcinoma (HCC) After PD1/PD-L1 Immune Checkpoint Inhibitors
Conditions
Interventions
Pembrolizumab
Regorafenib (Stivarga, BAY73-4506)
Locations
39
United States
University of Arizona Cancer Center
Tucson, Arizona, United States
City of Hope - Duarte Cancer Center
Duarte, California, United States
USC Norris Hospital and Clinics
Los Angeles, California, United States
University of California Irvine Medical Center
Orange, California, United States
Medical Oncology Hematology Consultants, PA
Newark, Delaware, United States
University of Miami Miller School of Medicine
Miami, Florida, United States
Start Date
February 3, 2021
Primary Completion Date
May 5, 2022
Completion Date
April 23, 2024
Last Updated
May 13, 2025
NCT07175441
NCT05969860
NCT06427941
NCT05842174
NCT07164313
NCT07118202
Lead Sponsor
Bayer
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions